Axiom Real-Time Metrics Announces Leadership Transition

TORONTO & GREENWICH, Conn.–(BUSINESS WIRE)–Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services that are used to enhance the efficiency of Phase I, II and III clinical trials and observational studies, announced today that Wayne Weaver, a highly experienced leader in the pharmaceutical services industry, has assumed the role of CEO, and Founder Andrew Schachter has transitioned to the role of Chairman of the Company.

Founded in 2001 and based in Toronto, Canada, Axiom is a leading e-clinical technology company that focuses on building best of breed Single-Sign-On Unified eClinical Solutions, inclusive of EDC, Data Management, Clinical Trial Management Systems, Randomization, Electronic Patient Reported Outcomes and other technology and service solutions for biotechnology and pharmaceutical sponsors conducting clinical trials. Great Point Partners, a Greenwich-based private equity firm focused on the health care industry, completed a growth recapitalization of the company in 2019.

Mr. Weaver previously served as an Executive Director at PPD (part of Thermo Fisher Scientific), one of the industry’s largest leading contract research organizations. Mr. Weaver brings to Axiom two-and-a-half decades of experience working with clients across a wide array of contract research services. He is deeply knowledgeable about the various needs of pharmaceutical customers and the challenges they face in their clinical trial programs, including the importance of timely reporting of data and trial key performance metrics.

“Axiom has established itself as a critical partner to its clients and is well positioned for growth, and we are thrilled to welcome Wayne to the team as CEO,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP. “Given his deep operational expertise and experience in pharmaceutical services, he is the right person to guide Axiom through its next stage.”

“I have been impressed with Axiom’s Fusion eClinical Suite platform and the mission-critical services it provides its customers,” said Mr. Weaver. “I look forward to working alongside the highly talented Axiom team to continue providing top-tier service to our clients and capitalizing on the opportunity for growth that Axiom has in front of it.”

“I am incredibly proud of the work that the team and I at Axiom have done over the last two decades to position itself as an industry leader, and I believe this move will enable Axiom to take it to yet another level,” said Andrew Schachter, Axiom Founder and Chairman. “I look forward to working closely with Wayne to drive our lofty goals and ambitions for Axiom’s bright future, while we focus on expanding Fusion’s capabilities and offerings and ensuring our clients’ successes across their clinical programs.”

About Axiom Real-Time Metrics

Axiom is celebrating 23 years of delivering hundreds of studies in dozens of countries. Since its founding in 2001, Axiom has delivered data-driven, powerful, and cost-effective eClinical Solutions and Services dedicated to small-to-medium life science companies. Axiom Fusion eClinical Suite is the most adaptable, Unified Platform that serves as the Connected Hub for all your Clinical Trial and operational data and reporting. Choose from 15+ unified modules on a single platform: EDC, DM, RTSM/IRT, CTMS, Inventory Management, ePRO, eConsent, Patient Portal, AE/SAE Tracking, Safety Database, Central/Local Lab, Imaging Management, eTMF, and 24/7 Project and Clinical Data Reporting. Axiom is an embedded partner dedicated to the success of your study, offering managed services such as: Data Management, On-Demand Data Analytics, Biostatistics, Clinical Management, eTMF Management and Quality/GDPR and Pharmacovigilance.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.


Prosek Partners

Artículos Relacionados